BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a research report on Wednesday, November 6th.

BioLineRx Stock Performance

NASDAQ:BLRX opened at $0.48 on Friday. The business’s 50-day moving average price is $0.51 and its two-hundred day moving average price is $0.62. BioLineRx has a twelve month low of $0.39 and a twelve month high of $1.93. The stock has a market cap of $38.01 million, a P/E ratio of -1.06 and a beta of 1.48. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $3.93 million. As a group, equities analysts predict that BioLineRx will post -0.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. PVG Asset Management Corp purchased a new position in BioLineRx during the second quarter valued at $70,000. Atria Investments Inc grew its holdings in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the period. Finally, CVI Holdings LLC bought a new stake in BioLineRx during the second quarter valued at about $462,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.